This website uses cookies. By using this website, you agree to our Cookie Policy.
September 24, 2014
Cadwalader is pleased to have advised Acorda Therapeutics, Inc., a leading biotechnology company, on its execution of a merger agreement to acquire Civitas Therapeutics, Inc., a privately-held biopharmaceutical company, for $525 million in an all cash transaction.
Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease. The acquisition also includes rights to Civitas’ proprietary ARCUS™ pulmonary delivery technology and manufacturing facility with commercial-scale capabilities based in Chelsea, MA.
The Cadwalader team was led by Corporate Co-chairs Jim Woolery and Christopher Cox, and included partners Ira Schacter (Corporate), Greg Patti (Corporate), Linda Swartz (Tax), Dorothy Auth (IP) and Andrew Forman (Antitrust).
About Acorda
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies including: AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed; ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy. This pipeline addresses a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. For more information, please visit the Company’s website at: www.acorda.com.
